Molecular and histopathologic predictors of distant failure in endometrial cancer

Jemal, 2003, Cancer statistics, 2003, CA Cancer J. Clin., 53, 5, 10.3322/canjclin.53.1.5 Karasek K, Faul C. Changing concepts in the management of endometrial cancer. Oncology (Huntingt) 1996;10:1099–106, 1110. Mariani, 2001, Locoregional recurrences in endometrial cancer, Eur. J. Gynaecol. Oncol., 22, 57 Aalders, 1984, Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients, Gynecol. Oncol., 17, 85, 10.1016/0090-8258(84)90063-5 Mariani, 2001, Hematogenous dissemination in corpus cancer, Gynecol. Oncol., 80, 233, 10.1006/gyno.2000.6058 Mariani, 2002, Predictors of lymphatic failure in endometrial cancer, Gynecol. Oncol., 84, 437, 10.1006/gyno.2001.6550 Mariani, 2002, Predictors of lymphatic failure in endometrial cancer, Gynecol. Oncol., 84, 437, 10.1006/gyno.2001.6550 Podratz, 1993, Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients, Am. J. Obstet. Gynecol., 168, 1206, 10.1016/0002-9378(93)90370-X Hetzel, 1992, HER-2/neu expression: a major prognostic factor in endometrial cancer, Gynecol. Oncol., 47, 179, 10.1016/0090-8258(92)90103-P Hamel, 1996, Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma, Gynecol. Oncol., 62, 192, 10.1006/gyno.1996.0214 Mariani, 2000, Pretreatment assessment of prognostic indicators in endometrial cancer, Am. J. Obstet. Gynecol., 182, 1535, 10.1067/mob.2000.107328 Prentice, 1986, A case-cohort design for epidemiologic cohort studies and disease prevention trials, Biometrika, 73, 1, 10.1093/biomet/73.1.1 FIGO stages—1988 revision: definitions of the clinical stages in carcinoma of the vulva. Gynecol Oncol 1989;35:125–6. Scully RE, Bonfiglio TA, Kurman RJ, et al. Histological typing of female genital tract tumours. 2nd ed. Berlin: Springer-Verlag, 1994, pp. 14–8. Key, 1993, New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope, Lab. Invest., 68, 629 Hedley, 1983, Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry, J. Histochem. Cytochem., 31, 1333, 10.1177/31.11.6619538 Vindelov, 1983, A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis, Cytometry, 3, 323, 10.1002/cyto.990030503 Gonchoroff, 1990, Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry, Cytometry, 11, 642, 10.1002/cyto.990110513 Baisch, 1975, Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle, Radiat. Environ. Biophys., 12, 31, 10.1007/BF02339807 Lanciano, 1993, The justification for a surgical staging system in endometrial carcinoma, Radiother. Oncol., 28, 189, 10.1016/0167-8140(93)90057-F Descamps, 1997, Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy, Gynecol. Oncol., 64, 54, 10.1006/gyno.1996.4511 Mayr, 1995, Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement—patterns of failure, Radiology, 196, 323, 10.1148/radiology.196.2.7617840 Inoue, 1996, The prognostic significance of vascular invasion by endometrial carcinoma, Cancer, 78, 1447, 10.1002/(SICI)1097-0142(19961001)78:7<1447::AID-CNCR11>3.0.CO;2-# DiSaia, 1985, Risk factors and recurrent patterns in Stage I endometrial cancer, Am. J. Obstet. Gynecol., 151, 1009, 10.1016/0002-9378(85)90371-0 Greven, 1993, Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence, Cancer, 71, 3697, 10.1002/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO;2-U Britton, 1990, DNA ploidy in endometrial carcinoma: major objective prognostic factor, Mayo Clin. Proc., 65, 643, 10.1016/S0025-6196(12)65126-X Reisinger, 1992, Preoperative radiation therapy in clinical stage II endometrial carcinoma, Gynecol. Oncol., 45, 174, 10.1016/0090-8258(92)90281-M Lanciano, 1990, Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium, Gynecol. Oncol., 39, 368, 10.1016/0090-8258(90)90268-P Mariani, 2001, Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement, Gynecol. Oncol., 83, 72, 10.1006/gyno.2001.6346 Mariani, 2002, Assessment of prognostic factors in stage IIIa endometrial cancer, Gynecol. Oncol., 86, 38, 10.1006/gyno.2002.6713 Mariani, 2000, Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?, Am. J. Obstet. Gynecol., 182, 1506, 10.1067/mob.2000.107335 Silvestrini, 1996, Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers, Clin. Cancer Res., 2, 2007 Pisani, 1995, HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma, Obstet. Gynecol., 85, 729, 10.1016/0029-7844(95)00037-R Podratz, 1999, Endometrial cancer: predicting nodal status via curettage?, Int. J. Gynecol. Cancer, 9, 83 Chiarugi, 1998, Cox-2, iNOS and p53 as play-makers of tumor angiogenesis, Int. J. Mol. Med., 2, 715 Zheng, 1996, p53 Overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes, Gynecol. Oncol., 61, 167, 10.1006/gyno.1996.0120